Walleye Trading’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-16,200
Closed -$163K 4987
2022
Q4
$163K Sell
16,200
-1,700
-9% -$31.9K ﹤0.01% 3732
2022
Q3
$401K Buy
17,900
+4,300
+32% +$124K ﹤0.01% 3099
2022
Q2
$337K Buy
13,600
+4,700
+53% +$130K ﹤0.01% 3301
2022
Q1
$345K Buy
8,900
+1,100
+14% +$42.6K ﹤0.01% 3315
2021
Q4
$456K Buy
+7,800
New +$442K ﹤0.01% 3053

Other funds holding FATE

Walleye Trading's FATE Position: Q1 2023 in Review

Walleye Trading sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 11,735 shares — an estimated $118K sold.

Walleye Trading first reported a position in FATE in Q2 2015 and held it in 7 quarters. The position peaked at $249K in Q4 2020. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Walleye Trading reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Walleye Trading sold 11,735 Fate Therapeutics shares in Q1 2023, an estimated $118K.
  • Walleye Trading first reported a position in Fate Therapeutics in Q2 2015 and held it in 7 quarters.
  • Walleye Trading's Fate Therapeutics position peaked at $249K in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Walleye Trading's 13F filing for Q1 2023, filed 15 May 2023.